Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company's therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
Industry, Sector and Symbol:
- Market Cap: $34.66 million
- Outstanding Shares: 9,903,000
- 50 Day Moving Avg: $3.34
- 200 Day Moving Avg: $3.22
- 52 Week Range: $2.41 - $4.84
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.97
- P/E Growth: 0.00
- Annual Revenue: $14 million
- Price / Sales: 2.48
- Book Value: $3.21 per share
- Price / Book: 1.09
- EBIDTA: ($6,730,000.00)
- Net Margins: -225.90%
- Return on Equity: -33.56%
- Return on Assets: -23.23%
- Debt-to-Equity Ratio: 0.05%
- Current Ratio: 2.25%
- Quick Ratio: 1.50%
- Average Volume: 91,508 shs.
- Beta: -0.72
- Short Ratio: 1.13
Frequently Asked Questions for Cesca Therapeutics (NASDAQ:KOOL)
What is Cesca Therapeutics' stock symbol?
Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."
How were Cesca Therapeutics' earnings last quarter?
Cesca Therapeutics Inc. (NASDAQ:KOOL) posted its quarterly earnings data on Tuesday, February, 16th. The company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.05. The business earned $3.29 million during the quarter, compared to analysts' expectations of $4.32 million. Cesca Therapeutics had a negative return on equity of 33.56% and a negative net margin of 225.90%. View Cesca Therapeutics' Earnings History.
When will Cesca Therapeutics make its next earnings announcement?
Who are some of Cesca Therapeutics' key competitors?
Some companies that are related to Cesca Therapeutics include KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Sonoma Pharmaceuticals (SNOA), Catalyst Biosciences (CBIO), Onconova Therapeutics (ONTX), Argos Therapeutics (ARGS), Auxilium Pharmaceuticals (AUXL), Baxalta (BXLT), Horizon Therapeutics (HPTX), Ocera Therapeutics (TZYM), Transition Therapeutics (TTHI) and Vitae Pharmaceuticals (VTAE).
Who are Cesca Therapeutics' key executives?
Cesca Therapeutics' management team includes the folowing people:
- Xiaochun Xu, Chairman of the Board, Interim Chief Executive Officer
- Jeff Cauble, Principal Financial Officer, Principal Accounting Officer
- Venkatesh Ponemone, Executive Director of India Operations, Director of Clinical and Scientific Affairs
- Vivian Liu, Chief Operating Officer
- Kimberly Ellner, Vice President of Manufacturing and Global Supply Chain
- Russell M. Medford M.D., Ph.D., Director
- Joseph Thomis, Director
- James Xu, Director
- Mahendra S. Rao Ph.D., Independent Director
- Denis Michael Rhein, Independent Director
Who owns Cesca Therapeutics stock?
Cesca Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.62%). Company insiders that own Cesca Therapeutics stock include (Hong Kong) Ltd Boyalife and Kenneth Harris. View Institutional Ownership Trends for Cesca Therapeutics.
Who bought Cesca Therapeutics stock? Who is buying Cesca Therapeutics stock?
How do I buy Cesca Therapeutics stock?
Shares of Cesca Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cesca Therapeutics' stock price today?
MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Cesca Therapeutics stock can currently be purchased for approximately $3.50.
Consensus Ratings for Cesca Therapeutics (NASDAQ:KOOL) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cesca Therapeutics (NASDAQ:KOOL)
(Data available from 9/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/12/2017||Maxim Group||Reiterated Rating||Hold||Low|
|9/21/2015||HC Wainwright||Upgrade||Neutral -> Buy||$2.00||N/A|
Earnings History for Cesca Therapeutics (NASDAQ:KOOL)Earnings History by Quarter for Cesca Therapeutics (NASDAQ KOOL)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/13/2017||Q2 2017||($0.35)||$4.01 million||View||N/A|
|11/17/2016||Q1 2017||($0.34)||$3.77 million||View||N/A|
|2/16/2016||Q216||($0.07)||($0.02)||$4.32 million||$3.29 million||View||Listen|
|11/16/2015||Q116||($0.06)||($0.08)||$3.71 million||$2.80 million||View||Listen|
|9/17/2015||Q415||($0.11)||($0.06)||$4.08 million||$3.70 million||View||Listen|
|6/23/2015||Q315||($0.08)||($0.12)||$4.69 million||$4.04 million||View||Listen|
|2/12/2015||Q215||($0.08)||($0.11)||$4.08 million||$4.60 million||View||N/A|
|11/13/2014||Q115||($0.08)||$3.60 million||$3.70 million||View||N/A|
|5/15/2014||Q3 2014||($0.05)||($0.07)||$4.04 million||View||N/A|
|2/14/2014||Q214||($0.10)||$4.80 million||$4.50 million||View||N/A|
|8/29/2013||Q4 2013||($0.14)||$4.50 million||$4.10 million||View||N/A|
|11/13/2012||Q113||$0.06||$4.90 million||$4.10 million||View||N/A|
Earnings Estimates for Cesca Therapeutics (NASDAQ:KOOL)
Current Year EPS Consensus Estimate: $-4.5200 EPS
Next Year EPS Consensus Estimate: $-1.1800 EPS
Dividend History for Cesca Therapeutics (NASDAQ:KOOL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cesca Therapeutics (NASDAQ:KOOL)
Insider Ownership Percentage: 3.90%Insider Trades by Quarter for Cesca Therapeutics (NASDAQ:KOOL)
Institutional Ownership Percentage: 2.53%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/26/2016||(Hong Kong) Ltd Boyalife||Major Shareholder||Buy||6,102,942||$2.52||$15,379,413.84|| |
|11/10/2015||Kenneth Harris||Director||Sell||80,858||$0.60||$48,514.80|| |
|11/9/2015||Kenneth Harris||Director||Sell||48,468||$0.60||$29,080.80|| |
|11/6/2015||Kenneth Harris||Director||Sell||30,190||$0.60||$18,114.00|| |
|11/3/2015||Kenneth Harris||Director||Sell||10,510||$0.60||$6,306.00|| |
|11/2/2015||Kenneth Harris||Director||Sell||5,700||$0.60||$3,420.00|| |
|10/29/2015||Kenneth Harris||Director||Sell||8,632||$0.60||$5,179.20|| |
|9/2/2015||Matthew T. Plavan||CEO||Sell||17,271||$0.68||$11,744.28|| |
Headline Trends for Cesca Therapeutics (NASDAQ:KOOL)
Latest Headlines for Cesca Therapeutics (NASDAQ:KOOL)
Cesca Therapeutics (KOOL) Chart for Wednesday, September, 20, 2017